ClinicalTrials.gg
TerminatedNCT01850251Updated Aug 19, 2015

Effects of a Supplement Enriched in Hydroxymethylbutyrate and Vitamin D on Muscle Strength in Hip Fracture

A Phase 4 interventional study of Supplement with HMB and vitamin D and Standard nutritional supplement in Hip Fractures, sponsored by Hospital Clinic of Barcelona. Terminated at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2015-08-19.

Sponsored by Hospital Clinic of Barcelona · Phase 4, Interventional, and Supportive care

Why this study was terminated
Recruiting problems.
Phase
Phase 4
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether a nutritional supplement high in protein and energy, and enriched with hydroxymethylbutyrate (HMB) and vitamin D is more effective than a standard nutritional supplement high in protein and energy in improving muscle strength in elderly patients with hip fracture.

Read the detailed description

Hip fractures are the cause of substantial morbidity and mortality in elderly people. Nine months after hip fracture, patients still have a poorer quality of life compared to control subjects matched for age and sex.

After a hip fracture, many patients fail to return to their homes and their previous state of mobility. Acute hospital costs generated by this condition are substantial, although the costs in rehabilitation and special care in long-term community are even greater.

Patients with hip fracture are most likely to be frail elderly, and they are usually malnourished when the fracture occurs. Moreover, physiological aging is accompanied by functional losses and changes in the various organs and systems, including the musculoskeletal system, in which there is a progressive reduction of muscle mass, called sarcopenia. Approximately 30% of muscle mass is lost between the fifth and eighth decades of life and the percentage of muscle loss can reach 15% per decade after 70 years of age. Having established a correlation between the loss of muscle mass and loss of strength, sarcopenia has been associated with a risk of functional disability twice in men and thrice in women.

Hydroxymethylbutyrate (HMB) is a leucine metabolite produced in small quantities (0.3-0.4 g/d). Leucine effects on muscle metabolism appear to be due, in part, to HMB. In vitro experiments have observed that HMB attenuates proteolysis processes through the inhibition of various catabolic pathways and could stimulate protein synthesis. There are some evidences that administration of HMB in the elderly results in increases in muscle strength and functionality enhancements, compared to a control group.

In elderly people, low levels of vitamin D have been associated, among others, to decreased muscle strength, falls and fractures. The elderly have an increased risk of developing vitamin D deficiency due to less sun exposure, a decrease in the absorption and changes in the metabolism of this vitamin. Because muscle weakness is a clinical feature of vitamin D deficiency, it has been postulated that its deficiency could precipitate and increase muscle weakness and functional decline in older people.

Therefore, the study raises the possibility that an intervention consisting of a high protein, high calorie oral nutritional supplement enriched with HMB and vitamin D is more effective than a standard high protein, high calorie oral nutritional supplement in improving muscle strength.

02

Conditions studied

  • Hip Fractures

Keywords

  • Hip fractures
  • Ageing
  • Sarcopenia
  • Function
03

In context

Hip Fractures

848 studies on the registry are indexed under Hip Fractures; 160 are open to participants now.

This study's enrollment of 2 is below the median of 90 across 540 interventional studies indexed under Hip Fractures.

Browse Hip Fractures studies →

Lead sponsor

Hospital Clinic of Barcelona is the lead sponsor of 326 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 65 years of age after hip fracture surgery.
  • Ability to walk before fracture.

Exclusion criteria

Exclusion Criteria:

  • Chronic renal failure, defined as a glomerular filtration rate less than 60 mL/min/1.73 m2, or serum creatinine of 0.9 mg/dL in women or 1.2 mg/dL in men.
  • Following a diet with protein restriction.
  • Need for enteral or parenteral nutrition.
  • Need for medication with orexigenic or anabolic effect, or long-term corticosteroids.
  • Active neoplastic disease.
  • Cognitive impairment or major psychiatric disorder.
  • Lack of signed informed consent.
  • Any patient with inability to comply with treatment or not appropriate according to the investigator.
05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Supplement with HMB and vitamin D

    Oral administration of 440 mL (2 bottles) of nutritional supplement with HMB and vitamin D each day during 8 weeks.

    Dietary Supplement: Supplement with HMB and vitamin D

  • Active comparator
    Standard nutritional supplement

    Oral administration of 440 mL (2 bottles) of standard nutritional supplement each day during 8 weeks.

    Dietary Supplement: Standard nutritional supplement

Interventions

  • Dietary supplementSupplement with HMB and vitamin D

    High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.

    Also known as: Ensure Plus Advance

  • Dietary supplementStandard nutritional supplement

    High protein, high calorie nutritional supplement.

    Also known as: Ensure Plus High Protein

06

What researchers measure

Primary outcomes

  1. Change in bilateral knee extension test as a measure of isometric muscle strength.

    Changes from baseline in the knee extension test at 8 weeks will be conducted using a dynamometer.

    Time frame: Baseline and 8 weeks

Secondary outcomes

  1. Change in the Timed Up & Go test as a measure of function.

    Changes from baseline in the Timed Up \& Go functional test at 8 weeks.

    Time frame: Baseline and 8 weeks

Other outcomes

  1. Quality of life

    Change from baseline in quality of life at 8 weeks

    Time frame: Baseline and 8 weeks

07

Study locations

1 site
  • Hospital Clinic de Barcelona
    Barcelona, Catalonia 08036, Spain
08

References and documents

Publications

  • Fuller JC Jr, Baier S, Flakoll P, Nissen SL, Abumrad NN, Rathmacher JA. Vitamin D status affects strength gains in older adults supplemented with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and lysine: a cohort study. JPEN J Parenter Enteral Nutr. 2011 Nov;35(6):757-62. doi: 10.1177/0148607111413903. Epub 2011 Aug 1. PubMed 21807930 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2013
First posted
May 9, 2013
Start
Jun 2013
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Last update
Aug 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01850251
Collaborators
Abbott
Responsible party
Pere Leyes (Specialist, Hospital Clinic of Barcelona) — Principal investigator
First posted
May 9, 2013
Start date
Jun 2013
Primary completion
Mar 2015
Completion
Mar 2015
Last update
Aug 19, 2015

Study contacts

Maria T Forga, MD
principal investigator · Hospital Clinic of Barcelona
Joan Trabal, RD, MS
study chair · Hospital Clinic of Barcelona
Pere Leyes, MD
study chair · Hospital Clinic of Barcelona
Salvi Prat, MD, PhD
study chair · Hospital Clinic of Barcelona
Margarita Navarro, MD
study chair · Hospital Clinic of Barcelona

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion